NCT07519187 2026-04-09
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
40 trialsNCT06986434 2026-04-08
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT07234721 2026-02-10
SL4903
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07123493 2026-01-28
Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
Beijing GoBroad Hospital
Phase EARLY_PHASE1 Terminated
NCT07337785 2026-01-22
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT07330895 2026-01-09
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT04656535 2026-01-07
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
Phase EARLY_PHASE1 Active not recruiting
NCT07240974 2025-11-21
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06148636 2025-11-04
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT06730256 2025-10-01
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT05634707 2025-09-22
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
Duke University
Phase EARLY_PHASE1 Active not recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT01748149 2025-08-03
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT07077330 2025-07-22
CAR19BCMA
Chinese PLA General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT04034446 2025-06-03
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Terminated
NCT06999031 2025-05-31
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
Phase EARLY_PHASE1 Recruiting
NCT06972602 2025-05-15
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Eye & ENT Hospital of Fudan University
Phase EARLY_PHASE1 Recruiting
NCT01184885 2025-05-04
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT06837389 2025-02-20
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT06684639 2024-12-20
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06298266 2024-03-07
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06104215 2023-10-27
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Recruiting
NCT06104241 2023-10-27
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1 Recruiting
NCT06045585 2023-09-21
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT03250520 2023-02-28
Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca
Hospital Infantil de Mexico Federico Gomez
Phase EARLY_PHASE1 Completed
NCT05559177 2022-09-29
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
Shanghai Pudong Hospital
Phase EARLY_PHASE1 Unknown
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04283006 2020-08-21
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04315584 2020-03-24
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities
University of Virginia
Phase EARLY_PHASE1 Unknown
NCT04169932 2019-11-20
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04028440 2019-09-26
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT04011293 2019-07-08
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Shandong University
Phase EARLY_PHASE1 Unknown
NCT02646319 2019-06-06
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03799913 2019-04-10
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT02623582 2017-10-17
CD123 Redirected Autologous T Cells for AML
University of Pennsylvania
Phase EARLY_PHASE1 Terminated
NCT01959477 2015-08-13
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed